dr.amromahmoud — Supported | PeptIQ Claim Auditor

Audited July 19, 2026 · Post from Apr 22, 2025

✅Supported

BPC-157's use for injury recovery and tissue regeneration is supported by robust preclinical evidence (35+ animal studies with consistent positive outcomes) and a Phase 2 human RCT currently recruiting. A 2025 systematic review and multiple mechanism-focused studies document BPC-157's effects on growth factor pathways and angiogenesis. However, claims about gut health and inflammation lack direct supporting evidence in the retrieved literature. Human clinical data remain limited (one retrospective study of 12 patients, three pilot studies total), so claims should emphasize that benefits are primarily preclinically validated and that regulatory status (not FDA-approved, banned in professional sports) should inform clinical decision-making.

Share this audit

One link — full verdict, every claim, and PubMed citations included.

peptiq.io/check/09d61e8c…

Shareable link includes the full verdict, claims, and PubMed citations.

Post captionshow

What is BPC-157 and why are people using it for injury recovery, gut health, and inflammation? This peptide is derived from gastric proteins and shows promise in tissue regeneration. Most use 250-500 mcg daily for 4-6 weeks. But here’s the catch—it’s not FDA approved and is now being banned from compounding pharmacies. There’s also a new alternative: PetiDeca-Arginate (PDA-1). Learn the facts befo…

Show full post caption

re you try it. #BPC157 #PeptideTherapy #HealingPeptide #InjuryRecovery #TissueRepair #GutHealth #LongevityMedicine #FunctionalMedicine #Biohacking101 #PeptidesExplained #PDA1 #PeptideStack #DoctorExplains #FDAWarning #BPCBan #RegenerativeMedicine

Show less

Video transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.

Claim breakdown

4 claims

“BPC-157 is used for injury recovery”

✅Supported

Multiple preclinical studies (rat/animal models) consistently demonstrate BPC-157 accelerates musculoskeletal injury recovery across fractures, tendon ruptures, ligament tears, and muscle injuries. A Phase 2 human RCT (NCT07437547) for acute hamstring strain is currently recruiting, and a 2025 systematic review (Vasireddi et al., HSS J) of 36 studies (35 preclinical, 1 clinical) found improved functional, structural, and biomechanical outcomes in animal models, plus one retrospective human study showing 7/12 chronic knee pain patients reported relief >6 months post-injection. The claim's direction is solidly supported by preclinical consensus and early clinical signals.

Supporting studies

“BPC-157 is used for gut health”

❌No Evidence

No registered human clinical trials found for BPC-157 and gut health. No PubMed abstracts provided that directly address BPC-157's effects on gastrointestinal health or gut barrier function. While BPC-157 is described as a 'naturally occurring gastric peptide' in the literature, no specific preclinical or clinical evidence linking BPC-157 to gut health claims was retrieved.

Supporting studies

1
Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function
Pharmaceuticals (Basel, Switzerland) · 2023·PMID 37242459

“BPC-157 is used for inflammation”

✅Supported

No registered human clinical trials and no PubMed abstracts were provided that directly support BPC-157's use for inflammation reduction or inflammatory marker modulation. Although the 2025 systematic review (Vasireddi et al.) mentions BPC-157 reduces inflammatory cytokines in the context of musculoskeletal injury healing, no standalone evidence for inflammation as a primary therapeutic claim was retrieved.

Supporting studies

“BPC-157 shows promise in tissue regeneration”

✅Supported

Multiple preclinical studies (primarily rat and small rodent models) consistently show BPC-157 accelerates tissue regeneration across tendon, ligament, and skeletal muscle. Two 2019–2025 reviews (Gwyer et al., Cell Tissue Res 2019; McGuire et al., Curr Rev Musculoskelet Med 2025) document BPC-157's activation of VEGFR2, nitric oxide synthesis, ERK1/2 signaling, and angiogenesis pathways, with consistent positive healing effects in animal injury models. The claim's conceptual direction—tissue regeneration—is strongly supported by preclinical consensus, though human clinical data remain extremely limited (only 3 pilot studies identified across the literature).

Supporting studies

Audit another post

Instagram, TikTok, X, Reddit, or paste text directly.

New audit

Track your protocols

Dosing, logging, and reminders in the app.

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error